Ascentage Pharma Group International Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Ascentage Pharma Group International ha aumentado sus beneficios a una tasa media anual de 0.5%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento anual de 11.7%. Los ingresos han ido creciendo a una tasa media de 66.1% al año.

Información clave

0.5%

Tasa de crecimiento de los beneficios

23.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	11.0%
Tasa de crecimiento de los ingresos	66.1%
Rentabilidad financiera	-1,310.6%
Margen neto	-417.0%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Ascentage Pharma Group International. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SZSC:6855 Ingresos, gastos y beneficios (CNY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	222	-926	376	707
30 Sep 23	239	-902	363	709
30 Jun 23	257	-879	349	712
31 Mar 23	233	-881	339	727
31 Dec 22	210	-883	328	743
30 Sep 22	160	-848	299	767
30 Jun 22	111	-812	270	790
31 Mar 22	69	-797	231	778
31 Dec 21	28	-782	191	766
30 Sep 21	25	-759	167	699
30 Jun 21	23	-735	143	631
31 Mar 21	18	-706	137	598
31 Dec 20	12	-678	130	565
30 Sep 20	14	-922	146	540
30 Jun 20	15	-1,167	162	516
31 Mar 20	15	-1,324	162	490
31 Dec 19	15	-1,481	162	464
30 Sep 19	11	-1,171	133	418
30 Jun 19	7	-862	104	372
31 Mar 19	7	-604	97	311
31 Dec 18	7	-345	90	250
31 Dec 17	6	-119	26	119
31 Dec 16	8	-108	22	103

Ingresos de calidad: 6855 actualmente no es rentable.

Margen de beneficios creciente: 6855 actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 6855 no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 0.5% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 6855 en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: 6855 no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (22.1%).

Rentabilidad financiera

Alta ROE: 6855 tiene una rentabilidad financiera negativa (-1310.61%), ya que actualmente no es rentable.

Ascentage Pharma Group International Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022)

Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024

First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022)

Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023

Full year 2022 earnings released: CN¥3.35 loss per share (vs CN¥3.07 loss in FY 2021)

First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021)

Recent updates

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022)

Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024

Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia

Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib

Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR

Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients

Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports

Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc

Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia

Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE

First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022)

Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial

Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023

Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax

Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All)

Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST

Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting

Full year 2022 earnings released: CN¥3.35 loss per share (vs CN¥3.07 loss in FY 2021)

Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million.

Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax

Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib

Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License

Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies

Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B

Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb

Co-Founder recently bought HK$159k worth of stock

Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting

Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential

First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021)

Ascentage Pharma Group International to Report Q2, 2022 Results on Aug 26, 2022

High number of new directors

Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada

Ascentage Pharma Announces China National Medical Products Administration Accepts and Grants Priority Review Designation to Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML

Ascentage Pharma Group International Announces Ind Clearance by the Us Fda for First-In-Human Study of Novel Eed Inhibitor Apg-5918

Ascentage Pharma Group International Releases Results from A Phase I Study of the Company's Novel Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R Nhl) at the 2022 European Hematology Association Hybrid Congress

Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL

Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC

Ascentage Pharma Group International Releases the Updated Results from A Phase II Study of the Mdm2-P53 Inhibitor Alrizomadlin (APG-115) Plus Pembrolizumab in Adults and Children with Various Solid Tumors in A Poster Discussion Session At the ASCO Annual Meeting

Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development

High number of new directors

Ascentage Pharma Group to Present Latest Clinical Data of Bcl-2 Inhibitorlisaftoclax (Apg-2575) in Patients with Relapsed/Refractory Non-Hodgkinlymphomas At 2022 European Hematology Association Hybrid Congress

Ascentage Pharma Group International Announces Management Changes, Effective May 20, 2022

Ascentage Pharma Group International Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in Embo Molecular Medicine

Less than half of directors are independent

Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

Ascentage Pharma Group International, Annual General Meeting, May 19, 2022

Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including A China Study Demonstrating Complete Responses

Ascentage Pharma Announces CDE's Approval for the Phase II Pivotal Study in China of the Bcl-2 Inhibitor Lisaftoclax (APG-2575) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Clover Biopharmaceuticals, Ltd. and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human Trail-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis

Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib

Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Grants Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma

Ascentage Pharma Reports the Phase Ib Results of the Dual Bcl-2/Bcl-Xl Inhibitor, Apg-1252

First half 2021 earnings released: CN¥1.53 loss per share (vs CN¥1.53 loss in 1H 2020)

Ascentage Pharma Group International Receives Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma

Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors

Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs

Non-Executive Director recently sold HK$19m worth of stock

Forecast to breakeven in 2023

Ascentage Pharma to Announce Updated Results Demonstrating Clinical Potential of Alrizomadlin (APG-115) Plus Pembrolizumab in Patients with Advanced Solid Tumors that Had Failed Immunotherapies in Oral Presentation

Non-Executive Director has left the company

Full year 2020 earnings released: CN¥3.14 loss per share (vs CN¥12.69 loss in FY 2019)

Ascentage Pharma Group International to Report Fiscal Year 2020 Results on Mar 31, 2021

Desglose de ingresos y gastos
Beta